Current results and future applications of radioimmunotherapy management of non-Hodgkin's lymphoma

Abstract

Monoclonal antibodies labeled with radionuclides have become an important therapeutic tool in the treatment of patients with non-Hodgkin's lymphomas (NHL). At the present time, their use in the US is approved for patients with rituximab-resistant, low-grade, follicular or transformed NHL. Encouraging responses seen in the relapsed and refractory patients have prompted their evaluation in earlier disease or in other histologic sub-types either alone or in combination with conventional chemotherapy. Additionally, they have been included as preparative regimens for stem cell transplant protocols within the context of clinical trials. This review discusses the latest clinical trials and future directions of radioimmunoconjugates in the treatment of NHL, with emphasis on US Food and Drug Administration (FDA) approved radioimmunoconjugates, namely ¹³¹I-tositumomab and ⁹⁰Y-ibritumomab tiuxetan.

Keywords:

• Monoclonal antibody
• non-Hodgkin's lymphoma (NHL)
• radioimmunoconjugates
• radioimmunotherapy
• ¹³¹I-tositumomab
• ⁹⁰Y-ibritumomab tiuxetan